<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823081</url>
  </required_header>
  <id_info>
    <org_study_id>91128</org_study_id>
    <nct_id>NCT01823081</nct_id>
  </id_info>
  <brief_title>Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible eyes are randomized to two groups. Group A will receive three intravitreal
      injections of bevacizumab at 4 week intervals. In group B, three intravitreal injections of
      combined bevacizumab and fasudil will be performed with the same frequency.

      Best corrected visual acuity (BCVA) and central macular thickness (CMT) will be evaluated
      prior to injections and then every 4 weeks for 6 months. Fluorescein angiography will be
      performed at baseline and at weeks 12 and 24. The two groups will be compared in terms of
      BCVA and CMT changes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Snellen E-chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>central macular thickness</measure>
    <time_frame>6 months</time_frame>
    <description>spectral domain optical coherence tomography (SD OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Status of macular perfusion</measure>
    <time_frame>6 months</time_frame>
    <description>Heidelberg fluorescein angiogram (HRA II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>clinical examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Intravitreal bevacizumab (Avastin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined intravitreal fasudil and bevacizumab (Avastin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of bevacizumab (Avastin)</intervention_name>
    <arm_group_label>Intravitreal bevacizumab (Avastin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of fasudil and bevacizumab (Avastin)</intervention_name>
    <description>intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)</description>
    <arm_group_label>Combined intravitreal fasudil and bevacizumab (Avastin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients with diabetic macular edema (DME) and:

          -  Central macula thickness&gt; 250Î¼m

          -  Visual acuity &lt; 20/40

          -  No active proliferative diabetic retinopathy

          -  No history of intravitreal anti-VEGF drug injection or macular laser photocoagulation
             (MPC) within the past 3 months

        Exclusion Criteria:

          -  History of vitrectomy

          -  History of cataract surgery within the past 6 months

          -  History of glaucoma or uveitis

          -  Presence of any macular disorder other than DME

          -  Presence of traction on the macula

          -  Significant media opacity

          -  Serum creatinine&gt;3mg/ml
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Clinical Professor, Ophthalmic Research Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fasudil</mesh_term>
    <mesh_term>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

